FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third qu ...

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences, Inc. is launching a two-part research support initiative to enhance accessibility to cell analysis amid reduced government funding and global economic challenges [1][2][3] Group 1: Initiative Details - The first phase involves awarding a three-laser Cytek Northern Lights™ flow cytometer, which utilizes Full Spectrum Profiling™ technology for versatile assays [2][3] - The second phase will introduce a grant program for funding eligible research projects, assessed through a merit-based process overseen by a scientific advisory board [3] Group 2: Collaboration and Impact - Cytek's initiatives are part of an ongoing collaboration with the International Society for Advancement of Cytometry (ISAC) to improve access to advanced cytometry tools globally [4] - A previous donation of a Cytek Northern Lights™ flow cytometer to a lab in Argentina exemplifies the impact of collaboration in empowering scientists in underserved communities [4] Group 3: Company Commitment - Cytek is dedicated to democratizing access to flow cytometry, ensuring that labs of all sizes and budgets can utilize advanced tools for cellular insights [5] - The company emphasizes the importance of community engagement alongside technological innovation to benefit the entire scientific community [5][7]